Radiation Oncology Journal

  • 제34권2호
  • /
  • Pages.156-159
  • /
  • 2016
  • /
  • 2234-1900(pISSN)
  • /
  • 2234-3156(eISSN)
대한방사선종양학회 (The Korean Society for Radiation Oncology)
권호 표지
DOI QR코드

DOI QR Code

Delayed radiation-induced inflammation accompanying a marked carbohydrate antigen 19-9 elevation in a patient with resected pancreatic cancer

  • Mattes, Malcolm D. (Department of Radiation Oncology, West Virginia University School of Medicine) ;
  • Cardinal, Jon S. (Department of Surgery, West Virginia University School of Medicine) ;
  • Jacobson, Geraldine M. (Department of Radiation Oncology, West Virginia University School of Medicine)
  • 투고 : 2016.03.27
  • 심사 : 2016.06.03
  • 발행 : 2016.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Although carbohydrate antigen (CA) 19-9 is a useful tumor marker for pancreatic cancer, it can also become elevated from a variety of benign and malignant conditions. Herein we describe an unusual presentation of elevated CA 19-9 in an asymptomatic patient who had previously undergone adjuvant chemotherapy and radiation therapy for resected early stage pancreatic cancer. The rise in CA 19-9 might be due to delayed radiation-induced inflammation related to previous intra-abdominal radiation therapy with or without radiation recall induced by gemcitabine. After treatment with corticosteroids the CA 19-9 level decreased to normal, and the patient has not developed any evidence of recurrent cancer to date.

키워드

참고문헌

  1. Steinberg W. The clinical utility of the CA 19-9 tumorassociated antigen. Am J Gastroenterol 1990;85:350-5.
  2. Lamerz R. Role of tumour markers, cytogenetics. Ann Oncol 1999;10 Suppl 4:145-9. https://doi.org/10.1023/A:1008386130283
  3. Pearce S, Thornes H, Carr D, Tanner A. Diagnostic pitfall; interpretation of CA 19-9 concentrations in the presence of hepatic dysfunction. Gut 1994;35:707-8. https://doi.org/10.1136/gut.35.5.707
  4. Marks LB, Yorke ED, Jackson A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 2010;76(3 Suppl):S10-9. https://doi.org/10.1016/j.ijrobp.2009.07.1754
  5. National Cancer Institute, Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 [Internet]. Bethesda, MD: National Cancer Institute; c2016 [cited 2016 Jun 7]. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
  6. Mann DV, Edwards R, Ho S, Lau WY, Glazer G. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol 2000;26:474-9. https://doi.org/10.1053/ejso.1999.0925
  7. Maestranzi S, Przemioslo R, Mitchell H, Sherwood RA. The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA. Ann Clin Biochem 1998;35(Pt 1):99-103. https://doi.org/10.1177/000456329803500113
  8. Pines E, Slama JL, Holeman A, Ley G, Malbec D, Boudon P. Unusually high level of CA 19-9 in chronic pancreatitis. Gastroenterol Clin Biol 1995;19:641-2.
  9. Safi F, Roscher R, Beger HG. The clinical relevance of the tumor marker CA 19-9 in the diagnosing and monitoring of pancreatic carcinoma. Bull Cancer 1990;77:83-91.
  10. Petit JM, Vaillant G, Olsson NO, et al. Elevated serum CA19-9 levels in poorly controlled diabetic patients: relationship with Lewis blood group. Gastroenterol Clin Biol 1994;18:17-20.
  11. Kodama T, Satoh H, Ishikawa H, Ohtsuka M. Serum levels of CA19-9 in patients with nonmalignant respiratory diseases. J Clin Lab Anal 2007;21:103-6. https://doi.org/10.1002/jcla.20136
  12. Camidge R, Price A. Characterizing the phenomenon of radiation recall dermatitis. Radiother Oncol 2001;59:237-45. https://doi.org/10.1016/S0167-8140(01)00328-0
  13. Azria D, Magne N, Zouhair A, et al. Radiation recall: a well recognized but neglected phenomenon. Cancer Treat Rev 2005;31:555-70. https://doi.org/10.1016/j.ctrv.2005.07.008
  14. Friedlander PA, Bansal R, Schwartz L, Wagman R, Posner J, Kemeny N. Gemcitabine-related radiation recall preferentially involves internal tissue and organs. Cancer 2004;100:1793-9. https://doi.org/10.1002/cncr.20229
  15. Jeter MD, Janne PA, Brooks S, et al. Gemcitabine-induced radiation recall. Int J Radiat Oncol Biol Phys 2002;53:394-400. https://doi.org/10.1016/S0360-3016(02)02773-6
  16. Ganem G, Solal-Celigny P, Joffroy A, Tassy D, Delpon A, Dupuis O. Radiation myositis: the possible role of gemcitabine. Ann Oncol 2000;11:1615-6. https://doi.org/10.1023/A:1008353224251
  17. O'Regan KN, Nishino M, Armand P, Kelly PJ, Hwang DG, Di Salvo D. Sonographic features of pectoralis muscle necrosis secondary to gemcitabine-induced radiation recall: case report and review of current literature. J Ultrasound Med 2010;29:1499-502. https://doi.org/10.7863/jum.2010.29.10.1499
  18. Matthews RH, Kadoch C, Ercal N. Alcohol as a potential contributing factor in radiation complications. Clin Adv Hematol Oncol 2009;7:257-62.
  19. Reed GB Jr, Cox AJ Jr. The human liver after radiation injury: a form of veno-occlusive disease. Am J Pathol. 1966;48:597-611.
  20. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313-27. https://doi.org/10.1200/JCO.2006.08.2644